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Objectives. The purpose of this study was to determine risk
factors for adverse events following protamine administration
after cardiopulmonary bypass.
Background. Intravenous protamine administration is associ-
ated with a risk of severe systemic reactions. However, risk factors
for these events have not been well delineated, thus hampering
development of preventive strategies.
Methods. A case–control study nested within a cohort of
consecutive patients undergoing surgery requiring cardiopulmo-
nary bypass was performed. The primary case definition included
those events (pulmonary hypertensive and systemic hypotensive)
occurring within 10 min of protamine administration in the
absence of other measurable causes of hemodynamic compromise.
Results. Comparing the 53 cases to the 223 control subjects,
three risk factors were independently associated with events
(multivariable odds ratio [95% confidence interval]): neutral
protamine Hagedorn insulin use (8.18 [2.08, 32.2]); fish allergy
(24.5 [1.24, 482.3]), and a history of nonprotamine medication
allergy (2.97 [1.25, 7.07]). These risk factors demonstrated an
increasingly strong association with progressively more specific
case definitions. An estimated 39% of cardiopulmonary bypass
patients had one or more of these risk factors. Prior intravenous
protamine, central venous pressure prior to protamine, preoper-
ative ejection fraction and the need for inotropes when coming off
bypass did not exhibit statistically significant associations with
events (all p > 0.15). Prior protamine allergy was associated
specifically with an increased risk of pulmonary hypertension
(multivariable odds ratio 189; 95% confidence interval 13, 2,856).
Conclusions. Immunologic factors are important in predispos-
ing individuals to protamine reactions, and a substantial propor-
tion of patients are at considerably increased risk. Strategies to
reduce the risk of protamine-associated events are needed.
(J Am Coll Cardiol 1998;32:1916–22)
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Protamine, when administered intravenously to neutralize
heparin, is associated with occasionally severe systemic reac-
tions (1) that are associated with substantial morbidity and
mortality (2–7). Because of its routine use after cardiac surgery
requiring cardiopulmonary bypass (CPB) and its use after
other procedures that require heparin (8,9), hundreds of
thousands of patients are exposed to protamine each year in
the U.S. alone (10).
Putative risk factors for protamine reactions have been
proposed, mostly based on case reports and the possible
immunologic mechanism of protamine reactions. These possi-
ble risk factors include the prior use of protamine-containing
insulin preparations (neutral protamine Hagedorn [NPH] and
protamine–zinc insulin) (3,7,11–16), prior exposure to intrave-
nous protamine (14), fish allergy (4,17), prior vasectomy
(6,18,19), poor left ventricular function (1,20–22), circulatory
instability (1,23) and low cardiac filling pressures (1). Prior
allergic reactions to other medications may also serve as a
marker for increased risk of adverse events to drugs in general
(24–27). However, evidence that any of these are truly inde-
pendent risk factors for protamine reactions is lacking, and
results are often inconsistent among studies. These limitations
have prevented development of the proper approach to mini-
mizing the risk of these potentially life-threatening reactions.
The purpose of this study therefore was to use a case–
control study nested within a retrospective cohort study (28) to
identify clinical variables that are independently associated
with adverse events following protamine administration in
patients undergoing surgery requiring CPB.
Methods
Cohort population. All 2,684 patients who underwent sur-
gery requiring CPB at the Hospital of the University of
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Pennsylvania (HUP) from 1990 through 1994 were identified
for the study cohort by ICD-9-CM procedure code 39.61. The
14 subjects with more than one eligible surgical procedure
during the years studied had only one procedure chosen at
random for inclusion in the study. Five hundred and twenty-
five charts (19.6%) could not be located by the Medical
Records Department, and 55 (2.0%) were excluded because
they had insufficient data to determine if the patient met the
primary case definition (defined below). On the basis of review
of our computerized medical records database, there was no
difference in the age (mean age 63 versus 64 years; p 5 0.08)
or race (p 5 0.9) of subjects among those with charts available
compared with those without charts available; subjects with
charts available were somewhat less likely to be women (29%)
than subjects without charts available (36%; p , 0.01).
Twenty-one patients were excluded because they did not
receive protamine after surgery (because the patient either was
not put on CPB or died during the operation), and 14 because
they had a surgical complication (defined as any intraoperative
complication that required surgical repair) at the time of
protamine, leaving a total of 2,069 patients.
Case and control selection. Primary definition of cases.
Cases were defined in two stages. First, all adverse events
potentially related to protamine were identified from the
cohort if they occurred within 30 min of the initiation of
protamine, were prolonged (lasting longer than the 5-min
period of protamine infusion) and met one or more of the
following criteria: 1) a decrease in systemic arterial pressure
following protamine of $25% of baseline or a decrease of
$10% requiring inotropic medications, reinstitution of CPB or
use of an intra-aortic balloon pump (IABP); 2) an increase in
pulmonary artery pressure of at least 25%, resulting in a
decrease in systemic arterial pressure as defined in 1) above; 3)
noncardiogenic pulmonary edema, defined as any decrease in
PO2 requiring an increase in ventilatory support (increase in
percent oxygen delivered or ventilatory rate, or positive end-
expiratory pressure) in the absence of evidence of cardiac
failure (falling cardiac output or increase in pulmonary capil-
lary wedge pressure), and/or 4) bronchospasm (the use of
bronchodilator therapy for either an elevation of peak inspira-
tory airway pressures of greater than 5 mm Hg or wheezing).
These events included those that were preceded by pulmonary
hypertension, but clinically insignificant elevations of pulmo-
nary pressures were not considered as events. All patients at
HUP have hemodynamic data recorded every 5 min intraop-
eratively on standardized data collection forms. Therefore
events could be identified in the 98% of procedures with
complete hemodynamic data.
Next we excluded from the primary analysis any event that
occurred in the setting of other causes of hemodynamic
compromise at the time of protamine infusion (use of any
vasodilating medications, hypercarbia [PCO2 . 50], hypoxia [a
fall in PO2 of .2 percentage points requiring therapy] or
ischemia) and any event occurring more than 10 min after
initiation of protamine. Thus, the primary case definition was
any event that occurred within 10 min of protamine in the
absence of other measurable causes of hemodynamic compro-
mise, and combines some of the strictest criteria from pub-
lished studies (12,14,29,30). It is important to note that the
term “adverse event,” rather than “protamine reaction,” is
used explicitly to emphasize that, in any given patient, it is
impossible to know if an event is due to protamine alone, some
other event, or both.
Control subjects. Control subjects were selected at random
in a 4:1 ratio to cases from among all subjects in the cohort
without an adverse event. Similar to cases, control subjects
were excluded from the primary analyses if they were exposed
to other potential causes of hemodynamic compromise,
thereby avoiding any bias that could occur if the exclusion
criteria for control subjects differed from those for cases (31).
Data collection. To identify all adverse events, trained
abstracters, blinded to the study hypotheses, recorded intraop-
erative hemodynamic data from the anesthesiologists’ data
forms for all subjects in the cohort. All records of subjects with
adverse events and a 5% sample of control subjects were
rereviewed independently by one of the investigators (S.E.K.),
and in no case was either an adverse event missed or an
adverse event identified when one did not, in fact, occur. All
cases and control subjects then had their medical records
reviewed in detail by a different group of trained abstracters
using a structured data collection instrument to identify all a
priori risk factors (listed below), selected prior to the start of
the study, and potentially confounding variables. Abstracters
collected these data prior to reviewing the subjects’ anesthesia
records (which would identify adverse events), and used infor-
mation only if it was recorded in the medical records prior to
the administration of protamine. Data were available in more
than 98% of records for all variables of interest except central
venous pressure (CVP) (93.4% available), prior intravenous
protamine (67.8%) and ejection fraction (66.1%). Twenty-
seven records were randomly selected for reabstraction by a
different abstracter; agreement between abstracters was
greater than 90% for most variables.
Data analysis. Primary analysis of risk factors. The odds
ratio (OR) was used to estimate the relative risk of adverse
events for subjects with and without each risk factor. A priori
risk factors were: prior or current use of protamine-containing
insulin; prior exposure to intravenous protamine; fish allergy;
prior vasectomy; a history of protamine allergy; left ventricular
function, as measured by preoperative ejection fraction; circu-
Abbreviations and Acronyms
CI 5 confidence interval
CPB 5 cardiopulmonary bypass
CVP 5 central venous pressure
HUP 5 Hospital of the University of Pennsylvania
IABP 5 intra-aortic balloon pump
Ig 5 immunoglobulin
NPH 5 neutral protamine Hagedorn
OR 5 odds ratio
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latory instability, as measured by the need for inotropes when
coming off CPB (but prior to protamine); low cardiac filling
pressures, as measured by CVP prior to protamine (because
pulmonary capillary wedge pressures were not routinely mea-
sured in the operating room), and a history of prior allergic
reactions to any medications other than protamine. The chi-
square or Fisher’s exact statistic and the 95% confidence
intervals (CIs) for each OR were determined.
Multivariable logistic regression analysis was performed to
estimate the OR for each a priori risk factor after adjusting
simultaneously for all other risk factors and potential con-
founders. Potential confounders were included in the models if
their inclusion changed the unadjusted OR for any candidate
risk factor by more than 15% (32). Protamine allergy and
vasectomy could not be included in the multivariable analyses
because there were no exposed cases using the primary defi-
nition. Interactions between each putative risk factor and both
the other risk factors and the confounders were assessed using
the relevant product terms in the multivariable models.
Analysis by strictness of definition of “protamine reactions.”
To assess the specificity of the primary case definition and to
better evaluate whether putative risk factors were predicting
“protamine reactions” or just hemodynamic events unrelated
to protamine, cases were categorized by increasingly liberal
definitions of “protamine reactions”: 1) the primary definition;
2) events occurring within 20 min of protamine in the absence
of other causes of hemodynamic compromise; 3) all events
occurring within 20 min regardless of other causes, and 4) all
events occurring within 30 min. One would expect that vari-
ables that were truly risk factors for protamine-related events
would exhibit increasing ORs with increasingly strict defini-
tions of events if these definitions were increasingly specific for
protamine reactions, whereas variables that were not directly
related to protamine would not exhibit increasing ORs (33).
Analysis by severity and type of reaction. Because there are
different severities and mechanisms of reactions to protamine,
we performed secondary analyses to examine the association
between each risk factor and both the severity and type of
reactions. “Severe” hypotensive events were defined as a
decrease in blood pressure of at least 25% that required
treatment with inotropes, IABP or reinstitution of CPB, and
“moderately severe” events were all others. The odds of having
a “severe” event relative to the odds of having a “moderately
severe” event were then determined for each risk factor.
Reactions were also divided into those manifest solely as a
decrease in systolic blood pressure versus those manifest
initially as an increase in pulmonary pressure. This analysis was
limited to those subjects who had pulmonary artery pressures
measured during the 30 min after protamine.
All statistical analyses were performed using the SPSS
(version 6.1) and Stata (version 5.0) statistical programs, and
statistical significance was defined as a two-sided p value
,0.05. The study was approved by the University of Pennsyl-
vania Institutional Review Board.
Results
Adverse events. Table 1 presents the risks of adverse events
under differing case definitions. Overall, 230 procedures were
associated with an adverse event. Ninety-eight were excluded
from the primary case definition because they occurred more
than 10 min after protamine. Of the remaining 132 early
events, 78 were excluded because they received concomitant
vasodilating medications (six of these subjects also had other
exclusion criteria: one had hypercarbia, one had hypoxia and
four had ischemia prior to protamine), and one was excluded
for isolated ischemia, leaving a total of 53 who met the primary
case definition. No events meeting the primary case definition
manifest as isolated bronchospasm or pulmonary edema in the
absence of systemic hypotension or pulmonary hypertension.
Risk factors for adverse events. In unadjusted analysis,
higher CVP, a history of nonprotamine drug allergy, fish
allergy, need for inotropes and NPH insulin use (no subject
had used protamine–zinc insulin) were associated with either a
statistically significant increased, or trend toward an increased,
risk of adverse events (Table 2). Prior intravenous protamine
and ejection fraction were not associated with a significant
increase in events (Table 2), and there was no difference in the
risk of events among those with known status of these variables
versus those with missing data (p 5 0.30 for intravenous
protamine and p 5 0.80 for ejection fraction). The lack of
effect of prior intravenous protamine was not explained by the
use of potentially prophylactic therapies (intraoperative H1- or
H2-receptor blockers or corticosteroids within 24 h of prota-
mine [34–37]); subjects with prior intravenous protamine
exposure were no more likely than those without to receive
these therapies (OR 5 1.38; 95% CI: 0.70, 2.72), nor was prior
intravenous protamine associated with events in the subgroup
that did not receive prophylactic therapy (OR 5 1.02; 95% CI:
0.48, 2.18).
Table 1. Risk of Events by Definitions
Event Definition*
Number with Event
(Number at Risk 5 2,069)
Risk of Event
(95% Confidence Interval)
Primary definition 53 2.56% (1.92%, 3.34%)
Events within 20 min, in absence of
other etiologies
69 3.33% (2.60%, 4.20%)
All events within 20 min 190 9.18% (7.97%, 10.51%)
All events within 30 min 230 11.11% (9.79%, 12.55%)
*Event definitions in text.
1918 KIMMEL ET AL. JACC Vol. 32, No. 7
RISK FACTORS FOR PROTAMINE REACTIONS December 1998:1916–22
Under the primary definition, no case had a history of
protamine allergy. However, controls with a history of prota-
mine allergy (all noted in the cardiac catheterization labora-
tory) were significantly more likely than those without to
receive potentially prophylactic therapy (OR 5 8.53; 95% CI:
2.70, 27.0).
In multivariable analysis, only NPH use, fish allergy and
nonprotamine drug allergy were associated with a statistically
significant risk of adverse events (Table 2). None of the other
a priori risk factors were associated with a significant risk of
events. Removing fish allergy from the model, because of the
low number of unexposed subjects, did not substantively affect
the results for the other predictors. There also was no substan-
tive difference in the results when adjusting for prior intrave-
nous protamine or ejection fraction in the smaller subgroups of
subjects with known status of these variables. Among the
confounders (those not previously hypothesized as risk fac-
tors), only prior heart surgery was associated with events (OR
5.64, 95% CI: 1.16, 22.0). There also were no significant
interactions among any of the risk factors and either each
other or the confounders.
There were 101 cases (all adverse events, not limited to the
primary definition) and 213 (39%) control subjects with one or
more of the three a priori identified risk factors. If the
proportion of subjects with a risk factor in the rest of the
cohort population that were not selected as control subjects is
the same as for those selected (as would be expected given the
random selection process of control subjects), then the esti-
mated proportion of patients in the entire cohort with one or
more risk factor would be 39% ([101 cases 1 213 selected
control subjects 1 {39%z1,283 unselected control subjects}] 4
2,069).
Analysis by specificity of case definition. Figures 1 and 2
illustrate the multivariable ORs for each of the potential risk
factors when different definitions of adverse events were used.
As the possibility that adverse events were due to causes other
Figure 1. Association between risk factors and adverse events using
progressively more specific case definitions. Multivariable odds ratios
and 95% confidence intervals (bars) are plotted on a logarithmic scale
for risk factors that showed significant associations with the outcome
when using the primary definition of adverse events. All odds ratios are
adjusted for variables stated in footnote to Table 2. NPH 5 neutral
protamine Hagedorn. Circles 5 all events; diamonds 5 all events
within 20 min; squares 5 events within 20 min without other causes;
triangles 5 events within 10 min without other causes (primary
definition).
Table 2. Distribution of Risk Factors in Cases and Control Subjects and Associations of Risk Factors With Events Using Primary
Case Definition
Risk Factors
Cases
(n 5 53)
Controls
(n 5 223)
Univariate
Odds Ratio
(95% CI)
Multivariable*
Odds Ratio
(95% CI)
Drug allergy other than protamine 26 (49.1%) 63 (28.8%) 2.38 (1.29, 4.40) 2.97 (1.25, 7.07)
p 5 0.005 p 5 0.014
Ejection fraction (mean % 6 SD)† 50.7 6 17.6 49.7 6 19.0 1.03 (0.84, 1.26)‡ 1.35 (0.89, 2.05)‡
p 5 0.76 p 5 0.16
Fish allergy 2 (3.8%) 1 (0.4%) 8.71 (0.77, 97.9) 24.5 (1.24, 482.3)
p 5 0.09 p 5 0.035
History of protamine allergy 0 (0%) 4 (1.8%) 0.00 (0.00, 6.42) NC
p 5 1.00
Inotropes needed coming off bypass 31 (59.6%) 99 (45.2%) 1.79 (0.97, 3.31) 0.85 (0.34, 2.11)
p 5 0.06 p 5 0.73
Intraoperative central venous pressure
prior to protamine (mean mm 6 SD)
11.5 6 4.3 10.1 6 3.7 1.56 (1.05, 2.33)§ 0.97 (0.53, 1.77)§
p 5 0.027 p 5 0.91
NPH insulin use 7 (13.2%) 12 (5.4%) 2.65 (0.99, 7.10) 8.18 (2.08, 32.2)
p 5 0.045 p 5 0.003
Prior intravenous protamine† 19 (50.0%) 68 (47.6%) 1.10 (0.54, 2.26) 1.54 (0.36, 6.57)
p 5 0.79 p 5 0.56
Vasectomy 0 (0%) 0 (0%) NC NC
*All odds ratios are adjusted for age, gender, NPH use, fish allergy, nonprotamine drug allergy, need for inotropes coming off bypass (but prior to protamine),
central venous pressure, myocardial infarction in prior week, type of surgery, prior cardiac surgery, bypass time, need for intra-aortic balloon pump or left ventricular
assist device intraoperatively (but prior to protamine), body mass index, number of prior cardiac catheterizations and hemoglobin level prior to protamine. Models for
ejection fraction and prior intravenous protamine include all of the aforementioned variables plus ejection fraction and prior intravenous protamine, respectively.
†Analyses in subset of patients with known status of these variables. ‡Odds ratios are for each 10 percentage point increase in ejection fraction. §Odds ratios are for
each 5-mm increase in central venous pressure. CI 5 confidence interval; n 5 number; NC 5 not calculable; NPH 5 neutral protamine Hagedorn; SD 5 standard
deviation.
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than protamine decreased, the association between adverse
events and associated risk factors increased (Fig. 1). There was
no clear trend toward increasing ORs among risk factors that
were not associated with the primary definition of events (Fig.
2). Although the ORs did increase for prior intravenous
protamine and ejection fraction, none of these ORs was
statistically distinguishable from one.
Analysis by severity and type of event. The risk of severe
events (11 cases) was not statistically significantly different
from the risk of moderately severe events (42 cases) for any of
the risk factors studied using the primary definition of adverse
events (all p values $0.15). That is, none of the risk factors
were more strongly associated with severe than with moder-
ately severe events.
Among those with known pulmonary artery pressures, the
risk of “systemic hypotensive” events (80 events) was not
statistically different from the risk of “pulmonary hyperten-
sive” events (14 events) within 30 min of protamine for any of
the risk factors (all p values .0.15) except prior protamine
allergy. Subjects with a history of protamine allergy had a
15-fold increased risk of having a pulmonary hypertensive
event relative to a systemic hypotensive event (p 5 0.047). For
those with a history of a protamine allergy, the univariate OR
for pulmonary hypertensive events relative to no events was
12.3 (95% CI: 2.34, 64.9), and the multivariable OR was 189
(95% CI: 12.6, 2,856).
Discussion
Study findings. This study demonstrates that NPH insulin
use, fish allergy and a history of nonprotamine medication
allergy are all independent risk factors for clinically important
adverse events following protamine administration. These risk
factors did not differ in their association with adverse events
based on their severity, nor did they differ with respect to the
type of event. The other a priori risk factors were not associ-
ated with an increased risk of events. However, definitive
conclusions cannot be drawn about the risk associated with
prior vasectomy and protamine allergy because of inadequate
numbers of exposed subjects when using our primary defini-
tion. In addition, control subjects with a history of protamine
allergy were more likely to receive potentially prophylactic
therapies prior to protamine, and the documentation of prior
protamine reactions is likely to be poor (38), thus possibly
masking an overall association. However, a history of prota-
mine allergy did increase the risk of pulmonary hypertensive
events, although this isolated finding from a subgroup analysis
must be interpreted cautiously.
Definitive evidence proving or disproving an association
between the risk factors examined in this study and protamine
reactions has previously been lacking because of limited power
in some studies (12,16,39), the absence of control groups in
case reports and case series (4,6,17,19,29), the possibility that
some reports of adverse events were biased by knowledge of
putative risk factors and a lack of multivariable analyses in all
studies.
The analyses by specificity of the definition of adverse
events also strongly support the hypothesis that the risk factors
identified are associated specifically with protamine reactions.
If the study had used any of the less strict definitions, the
significant finding among subjects with fish allergy and non-
protamine drug allergy would have been missed, despite the
greater number of subjects included in the analyses using these
more liberal definitions. Although it is impossible to know for
sure if an event truly is related to protamine, our data suggest
that the definition of adverse events used in this study is
specific enough to identify previously postulated risk factors,
without being insensitive enough to miss potential factors.
Support for an immunologic mechanism of protamine reac-
tions. The etiology of protamine reactions may include true
allergic reactions (immunoglobulin [Ig]E-mediated or IgG-
mediated), anaphylactoid events (complement-mediated) or
direct toxicity (1,5,11,40,41). That serum IgE and IgG antibod-
ies are strong predictors for adverse events following prota-
mine (30) suggests that immune mechanisms are responsible
for a large proportion of protamine reactions. Although not
designed specifically to examine the mechanism of protamine
reactions, our study supports this hypothesis. Risk factors for
induction of a drug-specific immune response (i.e., prior
sensitization to protamine and fish proteins or an allergic
history) were associated with protamine-related events, but
nonimmunologic factors (e.g., cardiac function and filling
pressures) were not associated with events. In addition, there
appeared to be no difference in the effects of the immunologic
risk factors (i.e., no interactions) based on the presence or
absence of nonimmunologic factors that may contribute to the
elicitation of a clinically overt reaction in previously sensitized
Figure 2. Association between risk factors and adverse events using
progressively more specific case definitions. Multivariable odds ratios
and 95% confidence intervals (bars) are plotted on a logarithmic scale
for risk factors that did not show a significant association with the
outcome when using the primary definition of adverse events. All odds
ratios are adjusted for variables stated in footnote to Table 2, except
for the odds ratios for protamine allergy, which are unadjusted. The
odds ratios for protamine allergy for events defined as those occurring
within 10 min of protamine in the absence of other causes of
hemodynamic compromise are undefinable. The odds ratios for central
venous pressure are for each 5-mm increase, and the odds ratios for
ejection fraction are for each 10 percentage point increase. CVP 5
central venous pressure; EF 5 ejection fraction. Symbols as in Figure 1.
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subjects. This is not to suggest that nonimmunologic factors
could not increase the risk of adverse events following prota-
mine (14,22,30,42), only that immunologic ones appear to be
the strongest predictors.
Risk of protamine reactions. The overall incidence of clini-
cally significant adverse events is difficult to assess because this
was an observational study. Because protamine reactions are
diverse, mimic other complications and vary over a spectrum of
severity, only randomized trials of protamine alternatives or
prophylactic therapies will be able to determine the true
incidence of events attributable to protamine. Nonetheless, the
range of risk, 2.6% to 11%, is consistent with most prior
prospective and retrospective studies. Although our primary
definition certainly may include some non–protamine-related
events (i.e., the risk could be less than 2.6%), the analysis by
specificity of definitions suggests that a substantial proportion
of these events are related to protamine and that, in fact, some
events occurring at later times after protamine are probably
protamine reactions. In addition excluding patients with isch-
emia (which may be due to protamine [43]) or receiving
concomitant vasodilators may have excluded protamine reac-
tions. Thus, our primary definition may underestimate the
absolute risk.
Potential limitations. This study must be interpreted with
the usual cautions inherent in observational research. It is
possible that true associations between risk factors and adverse
events were not detected due to chance (type II error).
However, the 95% confidence intervals make it unlikely that
relative risks greater than two were not detected for most risk
factors, except for prior intravenous protamine. We also could
not assess the effects of rate of infusion of protamine because
this was not routinely recorded in the medical records; how-
ever, we routinely administer protamine slowly (over at least
5 min), making rate of infusion an unlikely risk factor in our
population. Type I error (identifying an association by chance)
is unlikely in this study because we purposely focused on a
limited number of biologically plausible risk factors that was
determined prior to the start of the study. Differential misclas-
sification of exposures could have biased our results, but this is
extremely unlikely given the methods used to ensure unbiased
collection of data on risk factors. Also, there was no difference
in the risk of events for subjects with, versus those without,
missing information for specific risk factors, suggesting a lack
of bias from this missing information. Our study also used
methods to minimize the possibility of misclassification of
outcomes, a major concern in all prior studies of protamine
reactions, and also demonstrated the specificity of our case
definition. Although nondifferential misclassification is still
possible, this would only underestimate the effects of the risk
factors identified. Selection bias is unlikely given that the
reason for missing charts should not in any way be related to
either the outcome or the exposures of interest in this study.
Finally, the generalizability of our findings is limited by the use
of a single tertiary-care hospital.
Conclusions. In summary, this study demonstrates that
NPH insulin use, fish allergy and nonprotamine drug allergies
are independent risk factors for clinically important adverse
events following protamine administration in patients under-
going surgery requiring CPB. Prior protamine allergy may be a
risk factor specifically for pulmonary hypertensive events, but
further study is needed to validate this finding. The study also
derives a definition of protamine-related events that should be
useful in future studies exploring strategies to reduce the risk
of these events. Based on our results, a substantial proportion
of patients undergoing CPB are at considerably increased risk
of events that have been associated with important morbidity
and mortality. Because there are no clearly proven, effective
approaches to preventing protamine reactions, further
progress must be made in developing prophylactic strategies
(41,44,45) and protamine substitutes (46,47), targeting the
large number of patients at increased risk for adverse events
following intravenous protamine.
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